Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (471-480 of 584) with videos related to

Pageof 59
Sort By:
Blood|July 10, 2013
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapyFarhad Ravandi, Jeffrey L Jorgensen, Deborah A Thomas, et al.
Cancer|July 17, 2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemiaKoji Sasaki, Hagop M Kantarjian, Tapan Kadia, et al.
JAMA Oncology|July 17, 2015
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical TrialAnimesh Pardanani, Claire Harrison, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End ResultsKoji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Cancer|April 8, 2017
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approachPrajwal Chaitanya Boddu, Hagop M Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived SpecimensKatja Karjalainen, Diana E Jaalouk, Carlos Bueso-Ramos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2024
Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are BreastfeedingJorge E Cortes, Elisabetta Abruzzese, Elyce H Cardonick, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 17, 2013
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phaseMaro Ohanian, Hagop M Kantarjian, Alfonso Quintas-Cardama, et al.
American Journal of Hematology|March 16, 2017
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphomaNicholas J Short, Hagop M Kantarjian, Heidi Ko, et al.
Pageof 59

Showing results (471-480 of 584) with videos related to

Sort By:
Pageof 59
Blood|July 10, 2013
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapyFarhad Ravandi, Jeffrey L Jorgensen, Deborah A Thomas, et al.
Cancer|July 17, 2019
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemiaKoji Sasaki, Hagop M Kantarjian, Tapan Kadia, et al.
JAMA Oncology|July 17, 2015
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical TrialAnimesh Pardanani, Claire Harrison, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End ResultsKoji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Cancer|April 8, 2017
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approachPrajwal Chaitanya Boddu, Hagop M Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived SpecimensKatja Karjalainen, Diana E Jaalouk, Carlos Bueso-Ramos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2024
Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are BreastfeedingJorge E Cortes, Elisabetta Abruzzese, Elyce H Cardonick, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 17, 2013
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phaseMaro Ohanian, Hagop M Kantarjian, Alfonso Quintas-Cardama, et al.
American Journal of Hematology|March 16, 2017
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphomaNicholas J Short, Hagop M Kantarjian, Heidi Ko, et al.
Pageof 59